Summary:
A randomized, controlled, open- label, phase 3, Study of Melflufen/Dexamethasone compared with Pomalidomide/Dexamethasone for patients with relapsed refractory Multiple Myeloma who are refractory to Lenalidomide.
Qualified Participants Must:
• Male or female 18 years of age or older
•
Prior diagnosis of Multiple Myeloma (MM) with documented disease progression
•
Have had 2-4 prior lines of therapy including Lenalidomide and Proteasome Inhibitor
•
Life expectancy greater than or equal to 6 months
Qualified Participants May Receive:
Patients will be compensated for their participation, time and travel, also the drug will be provided